NSP
Insperity, Inc
stock NYSE

When using a future drug like that, my guy, you would use a percentage of it. Eliquis, if that is indeed the drug in question, is unknown what the market price will end up being. I'm using 10% as 2% seems ridiculously conservative. The average drop off from branded to generic is 80% to 85%, so my 90% drop seems much more realistic than your 98%. At 2.7 billion, accounting for market penetration and NSP values - I would put ELTPs expected revenue at $150 million. Then I would additionally discount it based on chance of approval and time to wait to hit the market (2027 was my aggressive assumption based on some legal challenges to the patents, but 2028 is acceptable as well.), which would come to approximately $15 to $30 million in revenue that I would attribute in buyout value. As time goes on, that number would increase as the value of the potential launch would push it closer to 100% of the $150 million value.

When using a future drug like that, my guy, you would use a percentage of it. Eliquis, if that is indeed the drug in question, is unknown what the market price will end up being. I'm using 10% as 2% seems ridiculously conservative. The average drop off from branded to generic is 80% to 85%, so my 90% drop seems much more realistic than your 98%. At 2.7 billion, accounting for market penetration and NSP values - I would put ELTPs expected revenue at $150 million. Then I would additionally discount it based on chance of approval and time to wait to hit the market (2027 was my aggressive assumption based on some legal challenges to the patents, but 2028 is acceptable as well.), which would come to approximately $15 to $30 million in revenue that I would attribute in buyout value. As time goes on, that number would increase as the value of the potential launch would push it closer to 100% of the $150 million value.